tera gold 2013 two-drug - JMK

Medical: the company is mainly engaged in research and development, production and sales of percutaneous coronary intervention medical equipment. Is the high-end medical equipment capable of forming strong competition with foreign products in the area of one of the smaller enterprises. Our main products include intravascular drug used in treatment of coronary heart disease (Sirolimus)-eluting stent system, Coronary Stent delivery system, PTCA balloon GuideCentral venous catheter tube, drug, and so on. Main products of the company's subsidiary Shanghai shape for closure of patent ductus arteriosus (PDA) blocking devices, atrial septal defect (ASD) block, Ventricular septal defect (VSD) Occluder; subsidiary of heaven and Earth and main class products for anesthesia tera gold, cardiac catheterization Interventional medical products with sheath and wire; subsidiary of guardian Golden sailsProducts for the treatment of heart disease WINMEDIC 2000 angiography machine, and so on. Company's carrier-free drug-eluting stent is expected to grow at high speed. No carrier in drug-eluting stent in patients with higher security requirements with unique, irreplaceable role, such as short-term needs surgery in some patients, drug-eluting stent using vector need long-term taking of blood coagulation drugs, will probably not be ableOperation. So the company first on the security requirements of better promoting carrier-free drug-eluting stent in patients with. Of drug-eluting stent with no carrier is expected to gradually promote, share of the revenue of company support in the future will be more and more high. Mergers and acquisitions overseas dealers Comed company. According to the company, Comed is a company specializing in cardiovascular interventional and surgicalEquipment sales distributors, sales channels covering Europe eq2 platinum, North America, the Middle East, Latin America and other countries. From now, 10 Comed company turnover of EUR 7.8 million, its rapid revenue growth, sales revenue of nearly six years an average annual compound growth rate of 28.3%. Merging Comed company helps companies to expand overseas markets, lifting productsLicensing and product certification faster. Company has passed the certification of the variety can be made directly through Comed's channel sales and broaden sales market, make rapid breakthroughs in overseas sales. Taking into account the cultural, differences such as management, the acquisition of the company relatively cautious, and increase access to Comed 70% stake in the company. The move ComEd stability played an important role in the development of the company. In addition, the company's research and development capabilities in an industry-leading position, the company accumulated powerful development force, carrier-free drug-eluting stent development and approval is the best example. Now research products of the company are mainly concentrated in the bracket system and heart valves. Specific research product may be listed in order: 2013 two-drug, antibody scaffoldsDecember 2014 fully biodegradable scaffold (magnesium stent, polymer degradation of stents); 2014 left atrial appendage occlusion June 2015 transcatheter valve (bio-valve: through the femoral artery enters. Without the need for open-chest). On the secondary market, the unit after shocks in the early adjustment risk has been released. But in February, and small-cap stocks have strongOccasion of the rebound, company shares are not active, belong to the evident stagnation unit. Established rebounded as the market trends, shares rose strongly complement requirements, expected future still is expected to amount to meet up again, it is recommended that investors pay due attention. var selfURL="http://quotes.cnfol.com/block/7,039 "; Online statement Gold: gold online reprint of the above content, does not indicate that confirm the description, for investors ' reference only and does not constitute investment advice. Investor operations accordingly blade & soul gold, at your own risk.